<DOC>
	<DOCNO>NCT02312973</DOCNO>
	<brief_summary>The study investigate pharmacokinetics ( absorption , distribution , elimination ) molidustat intake single 75 mg tablet subject renal impairment require hemo- peritoneal dialysis compare age-and gender-matched healthy subject . In addition , effect molidustat hormone erythropoietin evaluate well safety tolerability molidustat .</brief_summary>
	<brief_title>To Investigate Pharmacokinetics ( Absorption , Distribution , Elimination ) , Safety Tolerability Single Oral Dose 75 mg Molidustat Tablet Male Female Subjects Requiring Hemo- Peritoneal Dialysis Compared Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Male female ( without childbearing potential ) Age : ≥18 ≤79 year age Body mass index ( BMI ) : ≥18 ≤34 kg/m2 Ethnicity : White Subjects severe renal impairment hemodialysis peritoneal dialysis , Healthy subject Women childbearing potential , pregnant lactate woman Use medication within 2 week precede study could interfere investigational product Positive result hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) , human immune deficiency virus 1 2 antibody ( HIV 1/2 Ab ) Exclusion period study simultaneous participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Peritoneal dialysis</keyword>
	<keyword>Erythropoietin</keyword>
</DOC>